{"prompt": "['Amended Clinical Trial Protocol No. 05', '15-Dec-2021', 'GZ402673-EFC13429 - alemtuzumab', 'Version number: 1', 'The EDSS will be performed by the neurologist at the following visits: Screening, D-7, M4, M8,', 'M12, M15, M18, M21, M24/at EOTP; every 6 months in Safety Monitoring Phase, and at every', 'relapse visit.', '9.2.1.2 Annualized relapse rate at Year 2', 'Subjects/parents/guardians will be instructed to contact their Investigator immediately should any', 'symptoms suggestive of an MS relapse appear. The subject must be examined as soon as possible,', 'within 7 days from the onset date of the relapse.', 'Relapses are defined as new or recurrent neurological symptoms not associated with fever or', 'infection, lasting at least 24 hours, and accompanied by new objective neurological findings upon', 'examination by the neurologist and documented by the functional system scores. The subject must', \"have objective signs on the neurologist's examination confirming the event.\", 'New or recurrent symptoms that occur less than 30 days following the onset of a relapse should be', 'considered part of the same relapse. The Investigator can, at his/her discretion, treat the patient', 'with corticosteroids.', 'Relapses will not be considered as AEs (see AE Section 10.4.3).', '9.2.1.3 Cognition test scores', '9.2.1.3.1 Brief visuospatial memory test - revised', 'The Brief Visuospatial Memory Test - Revised (BVMT-R) is a commonly used, commercialized,', 'assessment tool to measure visuospatial learning and memory abilities across research and clinical', 'settings.', 'A visual display of six simple figures arranged in a 2 X 3 matrix on separate pages is shown to', 'participants patients for three consecutive 10-second trials. After each trial, participants are to', 'draw as many designs as accurately as they can and in the correct location. They are again asked', 'to reproduce the designs in the exact layout after a 25-minute delay filled with other distractor', 'tasks. A forced-choice recognition trial is administered immediately following the delayed', 'memory trial. An optional copy trial is included at the end of the test where the participants are', 'asked to copy the figure display as accurately as they can. Scoring of the immediate and delayed', 'recall as well as copy trials are based on the accuracy of the drawings and the location of the', 'figures. For each figure, one point is awarded to each satisfactory domain resulting in a maximum', 'of 12 points per trial.', 'Brief Visuospatial Memory Test-Revised will be assessed at Screening, D-7, M4, M8, M12, M18,', 'M24/at EOTP; annually in Safety Monitoring Phase. Central scoring will be performed by an', 'independent rater who is blinded to treatments (ie, current DMT or alemtuzumab).', 'Property of the Sanofi Group - strictly confidential', 'Page 55', 'VV-CLIN-0254406: 5.0']['Amended Clinical Trial Protocol No. 05', '15-Dec-2021', 'GZ402673-EFC13429 - alemtuzumab', 'Version number: 1', '9.2.1.3.2 Symbol digit modality test', 'Cognitive impairment will be assessed using the Symbol Digit Modality Test (SDMT) Brief and', 'easy to administer, the SDMT has demonstrated remarkable sensitivity in detecting not only the', 'presence of brain damage, but also changes in cognitive functioning over time and in response to', 'treatment. The SDMT involves a simple substitution task that normal children and adults can', 'easily perform. Using a reference key, the examinee has 90 seconds to pair specific numbers with', 'given geometric figures. Responses can be written or oral, and for either response mode,', 'administration time is just 5 minutes. For this study, only ORAL form of response is desired', '(ie, patient does NOT write down the responses, instead, patient is instructed to verbally call out', 'the numbers that correspond to the symbols and the administer writes down his/her responses.', '9.2.2 Other secondary endpoints', '9.2.2.1 Pharmacokinetics', 'For patients receiving alemtuzumab, serum concentrations and PK parameters will be studied', '9.2.2.1.1. Sampling time', 'The sampling times for blood collection can be found in the Study Flow Chart Section 1.2.4 and', 'Section 1.2.5.', '9.2.2.1.2 Pharmacokinetics handling procedure', 'Special procedures for collection, storage, and shipment of plasma samples collected for', 'EFC13429 concentrations will be provided in a separate laboratory manual.', '9.2.2.1.3.3 Bioanalytical method', 'Details of the bioanalytical methods are described in Appendix B and detailed in a separate', 'laboratory manual.', '9.2.2.1.4 Pharmacokinetics parameters', 'The following PK parameters will be calculated, using noncompartmental methods from the', 'cumulative serum alemtuzumab concentrations. The parameters will include, but may not be', 'limited to the following Table 8:', 'Property of the Sanofi Group - strictly confidential', 'Page 56', 'VV-CLIN-0254406: 5.0']\n\n###\n\n", "completion": "END"}